Moderna's updated RSV vaccine disappoints with only 50% efficacy

Max Bayer

Pharma Reporter

Moderna reported that its vaccine was 50% effective at preventing lower respiratory disease following RSV infection, falling short of numbers reported by GSK and Pfizer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Moderna's updated RSV vaccine disappoints with only 50% efficacy

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble

Mod­er­na's up­dat­ed RSV vac­cine dis­ap­points with on­ly 50% ef­fi­ca­cy

Max Bayer

Pharma Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

Grail pi­o­neered mul­ti-can­cer tests. But the com­pa­ny’s rough pub­lic de­but shows the in­dus­try could be in trou­ble

Moderna's updated RSV vaccine disappoints with only 50% efficacy

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble